Life AI Net
الرئيسية
الأرشيف
الحاسبات
الدليل
النشرة البريدية
تسجيل الدخول
العربية
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
الرئيسية
الأرشيف
الحاسبات
الدليل
النشرة البريدية
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
تسجيل الدخول
الرئيسية
الأرشيف
الحاسبات
الدليل
More
مباشر
Endpoints News
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
BioPharma Dive
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
Lonza News
Stipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter
Cell
Single-cell mapping of regulatory DNA-protein interactions
Cell
Plasma signals of lung tumor promotion for molecular cancer prevention
Cell
Deep learning of functional perturbations from condensate morphology
FierceBiotech
At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts
Lonza News
Stipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter
10x Genomics Blog
10x Genomics Stock On Fire: Up 41% With 8-Day Winning Streak - Trefis
Labiotech
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
Lonza News
Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post
Eli Lilly
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
Endpoints News
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
BioPharma Dive
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
Lonza News
Stipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter
Cell
Single-cell mapping of regulatory DNA-protein interactions
Cell
Plasma signals of lung tumor promotion for molecular cancer prevention
Cell
Deep learning of functional perturbations from condensate morphology
FierceBiotech
At first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts
Lonza News
Stipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter
10x Genomics Blog
10x Genomics Stock On Fire: Up 41% With 8-Day Winning Streak - Trefis
Labiotech
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
Lonza News
Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post
Eli Lilly
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
الأرشيف
هذا المقال غير متوفر في الأرشيف.